Truepill

In September 2022, digital health unicorn Truepill conducted its fourth round of layoffs that year, with the company stating it impacted 20% of its full-time employees across departments including engineering, HR, design, IT, and finance. This followed a third round earlier in the year, which the company corrected to 8% of staff, not the initially reported 33%. Leadership attributed the cuts to investor requests to extend the company's financial runway amid broader economic pressures, informing affected employees their roles were no longer sustainable. The layoffs occurred as Truepill, a platform providing diagnostics, telehealth, and prescription services to other companies, faced industry challenges, including halting ADHD medication prescriptions earlier in 2022 due to growing concerns in digital health.

In August 2022, digital health unicorn Truepill conducted its third round of layoffs that year, cutting approximately 175 employees, which represented about one-third of its workforce. The company, valued at $1.6 billion, refocused on its core pharmacy operations after expanding into diagnostics and telehealth services. This restructuring followed regulatory scrutiny in the digital health sector and a need to secure further funding, marking a shift from its rapid growth during the COVID-19 pandemic.

Truepill, a digital health and pharmacy fulfillment platform, announced layoffs impacting approximately 15% of its workforce on June 8, 2022. The company's CEO cited a need to adapt to shifting market conditions and achieve long-term sustainable growth and profitability. While not disclosing exact figures, the reduction reflects a strategic shift toward greater financial discipline, despite the company's continued belief in its mission and platform value. The move underscores broader adjustments within the healthcare technology sector as companies navigate economic changes.

Truepill on 2022-04-14.